Motoi Hosoe

Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study

Huib A.M. Kerstjens, Jorge Máspero, Kenneth R. Chapman et al. · The Lancet Respiratory Medicine · 2020 · 157 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: A 12‐week, placebo‐controlled study

Masaharu Kinoshita, Sang Haak Lee, Liang‐Wen Hang et al. · Respirology · 2011 · 41 citations

Medicine, Internal Medicine, Pharmacotherapy +17

24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: A comparison with placebo and salmeterol

Naruhiko Sugihara, Shigeto Kanada, Michiko Haida et al. · Respiratory Medicine · 2010 · 22 citations

Pharmacy, Pharmacology, Pharmacotherapy +8

Efficacy, Safety and Pharmacokinetics of Indacaterol in Caucasian and Japanese Patients with Chronic Obstructive Pulmonary Disease

Motoi Hosoe, Ralph Woessner, Soichiro Matsushima et al. · Clinical Drug Investigation · 2010 · 16 citations

Medicine, Pharmacokinetics, Pharmacology +8

A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma

Roland Buhl, Ana-Maria Tanase, Motoi Hosoe et al. · Pulmonary Pharmacology & Therapeutics · 2020 · 16 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17